# US 2026/0007698 A1 · Peptides and engineered t cell receptors targeting vcy antigen and methods of use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0007698 A1
- Document ID: US20260007698A1
- Status: Published application
- Kind: A1
- Application number: 18/993,469
- Filed: 2023-07-10
- Published: 2026-01-08
- Earliest claimed: 2022-07-11
- Assignees: Board of Regents, The University of Texas System
- Applicants: Board of Regents, the University of Texas System
- Inventors: Cassian YEE; Ke PAN
- Web page: https://patentgrep.com/patent/US20260007698A1

## CPC

- A61K 35/17: Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes (when activated by a specific antigen A61K39/00)
- A61P 35/00: Antineoplastic agents
- C07K 7/06: having 5 to 11 amino acids
- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- C12N 5/0636: {T lymphocytes}
- C12N 15/86: Viral vectors
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2319/02: containing a signal sequence
- C07K 2319/03: containing a transmembrane segment
- C12N 2501/515: CD3, T-cell receptor complex
- C12N 2501/998: Proteins not provided for elsewhere
- C12N 2510/00: Genetically modified cells
- C12N 2740/13043: viral genome or elements thereof as genetic vector
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

This disclosure provides for engineered T cell Receptors (TCRs), cells comprising the TCRs, and methods of making and using the TCRs. The current disclosure relates to TCRs that specifically recognize epitope(s) from tumor antigen VCY CT. Accordingly, aspects of the disclosure relate to an engineered T-cell Receptors (TCRs), nucleic acids encoding the TCRs, and cells comprising the nucleic acids and TCRs. Also provided are compositions comprising the cells, nucleic acids, or engineered TCRs of the disclosure, methods of making the cells and methods of using the embodiments of the disclosure for therapeutic treatments.

## Claims

### Claim 1

A polypeptide comprising a single chain T-cell Receptor (TCR) comprising a TCR-a polypeptide and a TCR-b polypeptide, wherein the TCR-a polypeptide comprises a CDR1, CDR2, and CDR3 comprising the amino acid sequence of SEQ ID NOS: 6, 7, and 8, respectively, and the TCR-b polypeptide comprises a CDR1, CDR2, and CDR3 comprising the amino acid sequence of SEQ ID NOS: 12, 13, and 14, respectively.

### Claim 2

A polypeptide comprising an antigen binding variable region comprising a CDR3 comprising an amino acid sequence with at least 80% sequence identity to SEQ ID NO:8.

### Claim 3 (depends on 2)

The polypeptide of claim 2, wherein the CDR3 comprises the amino acid sequence of SEQ ID NO:8.

### Claim 4 (depends on 2, 3)

The polypeptide of claim 2 or 3, wherein the variable region comprises a CDR1, CDR2, and/or CDR3.

### Claim 5 (depends on 4)

The polypeptide of claim 4, wherein the variable region comprises a CDR1 with at least 80% sequence identity to SEQ ID NO:6.

### Claim 6 (depends on 4, 5)

The polypeptide of claim 4 or 5, wherein the variable region comprises a CDR2 with at least 80% sequence identity to SEQ ID NO:7.

### Claim 7 (depends on 5, 6)

The polypeptide of claim 5 or 6, wherein the variable region comprises a CDR1 comprising the amino acid sequence of SEQ ID NO:6 and/or a CDR2 comprising the amino acid sequence of SEQ ID NO:7.

### Claim 8 (depends on 2, 3, 4, 5, 6, 7)

The polypeptide of any one of claims 2-7, wherein the variable region comprises an amino acid sequence with at least 70% sequence identity to SEQ ID NO:4.

### Claim 9 (depends on 8)

The polypeptide of claim 8, wherein the variable region comprises the amino acid sequence of SEQ ID NO:4.

### Claim 10 (depends on 2, 3, 4, 5, 6, 7, 8, 9)

The polypeptide of any one of claims 2-9, wherein the polypeptide comprises a T cell receptor alpha (TCR-a) variable region.

### Claim 11 (depends on 10)

The polypeptide of claim 10, wherein the polypeptide comprises a TCR-a variable and constant region.

### Claim 12 (depends on 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The polypeptide of any one of claims 2-11, wherein the polypeptide further comprises a signal peptide.

### Claim 13 (depends on 12)

The polypeptide of claim 12, wherein the signal peptide comprises an amino acid sequence with at least 80% identity to SEQ ID NO:5.

### Claim 14 (depends on 13)

The polypeptide of claim 13, wherein the signal peptide comprises an amino acid sequence of SEQ ID NO:5.

### Claim 15

A polypeptide comprising an antigen binding variable region comprising a CDR3 comprising an amino acid sequence with at least 80% sequence identity to SEQ ID NO:14.

### Claim 16 (depends on 15)

The polypeptide of claim 15, wherein the CDR3 comprises the amino acid sequence of SEQ ID NO:14.

### Claim 17 (depends on 15, 16)

The polypeptide of claim 15 or 16, wherein the variable region comprises a CDR1, CDR2, and/or CDR3.

### Claim 18 (depends on 17)

The polypeptide of claim 17, wherein the variable region comprises a CDR1 with at least 80% sequence identity to SEQ ID NO:12.

### Claim 19 (depends on 17, 18)

The polypeptide of claim 17 or 18, wherein the variable region comprises a CDR2 with at least 80% sequence identity to SEQ ID NO:13.

### Claim 20 (depends on 18, 19)

The polypeptide of claim 18 or 19, wherein the variable region comprises a CDR1 comprising the amino acid sequence of SEQ ID NO:12 and/or a CDR2 comprising the amino acid sequence of SEQ ID NO:13.

### Claim 21 (depends on 15, 16, 17, 18, 19, 20)

The polypeptide of any one of claims 15-20, wherein the variable region comprises an amino acid sequence with at least 70% sequence identity to SEQ ID NO:10.

### Claim 22 (depends on 21)

The polypeptide of claim 21, wherein the variable region comprises the amino acid sequence of SEQ ID NO:10.

### Claim 23 (depends on 15, 16, 17, 18, 19, 20, 21, 22)

The polypeptide of any one of claims 15-22, wherein the polypeptide comprises a T cell receptor beta (TCR-b) variable region.

### Claim 24 (depends on 23)

The polypeptide of claim 23, wherein the polypeptide comprises a TCR-b variable and constant region.

### Claim 25 (depends on 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

The polypeptide of any one of claims 15-24, wherein the polypeptide further comprises a signal peptide.

### Claim 26 (depends on 25)

The polypeptide of claim 25, wherein the signal peptide comprises an amino acid sequence with at least 80% identity to SEQ ID NO:11.

### Claim 27 (depends on 26)

The polypeptide of claim 26, wherein the signal peptide comprises an amino acid sequence of SEQ ID NO:11.

### Claim 28

An engineered T-cell Receptor (TCR) comprising a TCR-a polypeptide and a TCR-b polypeptide, wherein the TCR-a polypeptide comprises a CDR3 comprising an amino acid sequence with at least 80% sequence identity to SEQ ID NO:8 and the TCR-b polypeptide comprises a CDR3 comprising an amino acid sequence with at least 80% sequence identity to SEQ ID NO:14.

### Claim 29 (depends on 28)

The TCR of claim 28, wherein the TCR-a polypeptide comprises a CDR3 comprising the amino acid sequence of SEQ ID NO:8 and the TCR-b polypeptide comprises a CDR3 comprising the amino acid sequence of SEQ ID NO:14.

### Claim 30 (depends on 28, 29)

The TCR of claim 28 or 29, wherein the TCR comprises a TCR-a polypeptide comprising a variable region comprising CDR1, CDR2, and CDR3 and a TCR-b polypeptide comprising a variable region comprising CDR1, CDR2, and CDR3.

### Claim 31 (depends on 30)

The TCR of claim 30, wherein the TCR-a polypeptide comprises a CDR1 with at least 80% sequence identity to SEQ ID NO:6 and/or the TCR-b polypeptide comprises a CDR1 with at least 80% sequence identity to SEQ ID NO:12.

### Claim 32 (depends on 31)

The TCR of claim 31, wherein the TCR-a polypeptide comprises a CDR1 comprising the amino acid sequence of SEQ ID NO:6 and the TCR-b polypeptide comprises a CDR1 comprising the amino acid sequence of SEQ ID NO:12.

### Claim 33 (depends on 30, 31, 32)

The TCR of any one of claims 30-32, wherein the TCR-a polypeptide comprises a CDR2 with at least 80% sequence identity to SEQ ID NO:7 and the TCR-b polypeptide comprises a CDR2 with at least 80% sequence identity to SEQ ID NO:13.

### Claim 34 (depends on 33)

The TCR of claim 33, wherein the TCR-a polypeptide comprises a CDR2 comprising the amino acid sequence of SEQ ID NO:7 and the TCR-b polypeptide comprises a CDR2 comprising the amino acid sequence of SEQ ID NO:13.

### Claim 35 (depends on 30, 31, 32, 33, 34)

The TCR of any one of claims 30-34, wherein the CDR1, CDR2, and CDR3 of the TCR-a polypeptide comprise the amino acid sequence of SEQ ID NO: 6, 7, and 8, respectively and wherein the CDR1, CDR3, and CDR3 of the TCR-b polypeptide comprise the amino acid sequence of SEQ ID NO:12, 13, and 14, respectively.

### Claim 36 (depends on 30, 31, 32, 33, 34, 35)

The TCR of any one of claims 30-35, wherein the TCR-a polypeptide comprises an amino acid sequence with at least 70% sequence identity to SEQ ID NO:4 and the TCR-b polypeptide comprises an amino acid sequence with at least 70% sequence identity to SEQ ID NO: 10.

### Claim 37 (depends on 36)

The TCR of claim 36, wherein the TCR-a polypeptide comprises the amino acid sequence of SEQ ID NO:4 and the TCR-b polypeptide comprises an amino acid sequence with at least 70% sequence identity to SEQ ID NO:10.

### Claim 38 (depends on 28, 29, 30, 31, 32, 33, 34, 35, 36, 37)

The TCR of any one of claims 28-37, wherein the TCR comprises a modification or is chimeric.

### Claim 39 (depends on 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38)

The TCR of any one of claims 28-38, wherein the TCR-a polypeptide and TCR-b polypeptide are operably linked.

### Claim 40 (depends on 39)

The TCR of claim 39, wherein the TCR-a polypeptide and TCR-b polypeptide are operably linked through a peptide bond.

### Claim 41 (depends on 39)

The TCR of claim 39, wherein the TCR is a single chain TCR.

### Claim 42 (depends on 40, 42)

The TCR of claim 40 or 42, wherein the TCR-a polypeptide and TCR-b polypeptide are on the same polypeptide and wherein the TCR-b is amino-proximal to the TCR-a.

### Claim 43 (depends on 40, 42)

The TCR of claim 40 or 42, wherein the TCR-a polypeptide and TCR-b polypeptide are on the same polypeptide and wherein the TCR-a is amino-proximal to the TCR-b.

### Claim 44 (depends on 40, 41, 42, 43)

The TCR of any one of claims 40-43, wherein the TCR comprises a linker between the TCR-a and TCR-b polypeptide.

### Claim 45 (depends on 40, 41, 42, 43, 44)

The TCR of one of claims 40-44, wherein the linker comprises glycine and serine residues.

### Claim 46

A peptide comprising at least 66% sequence identity to SEQ ID NO:15.

### Claim 47 (depends on 46)

The peptide of claim 46, wherein the peptide comprises SEQ ID NO:15.

### Claim 48 (depends on 46)

The peptide of claim 46, wherein the peptide comprises at least 6 contiguous amino acids of SEQ ID NO:15.

### Claim 49 (depends on 46)

The peptide of claim 46, wherein the peptide comprises at least 7 contiguous amino acids of SEQ ID NO:15.

### Claim 50 (depends on 46)

The peptide of claim 46, wherein the peptide comprises at least 8 contiguous amino acids of SEQ ID NO:15.

### Claim 51 (depends on 46, 47, 48, 49, 50)

The peptide of any one of claims 46-50, wherein the peptide comprises at least 77% sequence identity to SEQ ID NO:15.

### Claim 52 (depends on 46, 47, 48, 49, 50, 51)

The peptide of any one of claims 46-51, wherein the peptide comprises at least 88% sequence identity to SEQ ID NO:15.

### Claim 53 (depends on 46, 47, 48, 49, 50, 51, 52)

The peptide of any one of claims 46-52, wherein the peptide consists of 7 amino acids.

### Claim 54 (depends on 46, 47, 48, 49, 50, 51, 52)

The peptide of any one of claims 46-52, wherein the peptide consists of 8 amino acids.

### Claim 55 (depends on 46, 47, 48, 49, 50, 51, 52)

The peptide of any one of claims 46-52, wherein the peptide consists of 9 amino acids.

### Claim 56 (depends on 46)

The peptide of claim 46, wherein the peptide consists of SEQ ID NO:15.

### Claim 57 (depends on 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56)

The peptide of any one of claims 46-56, wherein the peptide is immunogenic.

### Claim 58 (depends on 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57)

The peptide of any one of claims 46-57, wherein the peptide is modified.

### Claim 59 (depends on 58)

The peptide of claim 58, wherein the modification comprises conjugation to a molecule.

### Claim 60 (depends on 58, 59)

The peptide of claim 58 or 59, wherein the molecule comprises an antibody, a lipid, an adjuvant, or a detection moiety.

### Claim 61 (depends on 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60)

The peptide of any of claims 46-60, wherein the peptide has 1, 2 or 3 substitutions relative to a peptide of SEQ ID NO:15.

### Claim 62 (depends on 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61)

A polypeptide comprising the peptide of any one of claims 46-61.

### Claim 63 (depends on 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62)

A composition comprising at least one MHC polypeptide and the peptide or polypeptide of any one of claims 46-62.

### Claim 64 (depends on 63)

The composition of claim 63, wherein the MHC polypeptide is and/or peptide is conjugated to a detection tag.

### Claim 65 (depends on 63, 64)

The composition of claim 63 or 64, wherein the MHC polypeptide and peptide are operatively linked.

### Claim 66 (depends on 65)

The composition of claim 65, wherein the MHC polypeptide and peptide are operatively linked through a peptide bond.

### Claim 67 (depends on 65)

The composition of claim 65, wherein the MHC polypeptide and peptide are operatively linked through van der Waals forces.

### Claim 68 (depends on 63, 64, 65, 66, 67)

The composition of any one of claims 63-67, wherein at least two MHC polypeptides are linked to one peptide.

### Claim 69 (depends on 63, 64, 65, 66, 67, 68)

The composition of any one of claims 63-68, wherein the average ratio of MHC polypeptides to peptides is 4:1.

### Claim 70 (depends on 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62)

A molecular complex comprising the peptide or polypeptide of any one of claims 46-62 and a MHC polypeptide.

### Claim 71 (depends on 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 70)

A peptide-specific binding molecule, wherein the molecule specifically binds to a peptide or polypeptide of any one of claim 46-62 or the molecular complex of claim 70.

### Claim 72 (depends on 71)

The binding molecule of claim 71, wherein the binding molecule is an antibody, TCR mimc antibody, scFV, nanobody, aptamer, or DARPIN.

### Claim 73 (depends on 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 70)

A method of producing peptide-specific immune effector cells comprising:
(a) obtaining a starting population of immune effector cells; and
(b) contacting the starting population of immune effector cells with a peptide or polypeptide of any one of claims 46-62 or the molecular complex of claim 70, thereby generating peptide-specific immune effector cells.

### Claim 74 (depends on 73)

The method of claim 73, wherein contacting is further defined as co-culturing the starting population of immune effector cells with antigen presenting cells (APCs), artificial antigen presenting cells (aAPCs), or an artificial antigen presenting surface (aAPSs); wherein the APCs, aAPCs, or the aAPSs present the peptide on their surface.

### Claim 75 (depends on 74)

The method of claim 74, wherein the APCs are dendritic cells.

### Claim 76 (depends on 73, 74, 75)

The method of any one of claims 73-75, wherein the immune effector cells are T cells, peripheral blood lymphocytes, NK cells, invariant NK cells, NKT cells.

### Claim 77 (depends on 73, 74, 75, 76)

The method of any one of claims 73-76, wherein the immune effector cells have been differentiated from mesenchymal stem cell (MSC) or induced pluripotent stem (iPS) cells.

### Claim 78 (depends on 77)

The method of claim 77, wherein the T cells are CD8+ T cells, CD4+ T cells, or γδ T cells.

### Claim 79 (depends on 77)

The method of claim 77, wherein the T cells are cytotoxic T lymphocytes (CTLs).

### Claim 80 (depends on 73, 74, 75, 76, 77, 78, 79)

The method of any one of claims 73-79, wherein obtaining comprises isolating the starting population of immune effector cells from peripheral blood mononuclear cells (PBMCs).

### Claim 81 (depends on 73, 74, 75, 76, 77, 78, 79, 80)

The method of any one of claims 73-80, wherein the starting population of immune effector cells is obtained from a subject.

### Claim 82 (depends on 81)

The method of claim 81, wherein the subject is a human.

### Claim 83 (depends on 81)

The method of claim 81, wherein the subject has cancer.

### Claim 84 (depends on 83)

The method of claim 83, wherein the cancer comprises a VCY CT antigen positive cancer.

### Claim 85 (depends on 84)

The method of claim 84, wherein the cancer comprises cancer cells that are positive for a peptide of SEQ ID NO:15.

### Claim 86 (depends on 83, 84, 85)

The method of any one of claims 83-85, wherein the subject has been determined to have a VCY CT antigen positive cancer.

### Claim 87 (depends on 86)

The method of claim 86, wherein the subject has been determined to have cancer cells that are positive for a peptide of SEQ ID NO:15.

### Claim 88 (depends on 83, 84, 85, 86, 87)

The method of any one of claims 83-87, wherein the subject has been diagnosed with the cancer.

### Claim 89 (depends on 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88)

The method of any one of claims 73-88, wherein the method further comprises introducing the peptide or a nucleic acid encoding the peptide into the dendritic cells prior to the co-culturing.

### Claim 90 (depends on 89)

The method of claim 89, where the peptide or nucleic acids encoding the peptide are introduced by electroporation.

### Claim 91 (depends on 89)

The method of claim 89, wherein the peptide or nucleic acids encoding the peptide are introduced by adding the peptide or nucleic acid encoding the peptide to the dendritic cell culture media.

### Claim 92 (depends on 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91)

The method of any one of claims 73-91, wherein the immune effector cells are co-cultured with a second population of dendritic cells into which the peptide or the nucleic acid encoding the peptide has been introduced.

### Claim 93 (depends on 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92)

The method of any one of claims 73-92, wherein a population of CD8 or CD4-positive and peptide MHC tetramer-positive T cells are purified from the immune effector cells following the co-culturing.

### Claim 94 (depends on 93)

The method of claim 93, wherein a clonal population of peptide-specific immune effector cells are generated by limiting or serial dilution followed by expansion of individual clones by a rapid expansion protocol.

### Claim 95 (depends on 94)

The method of claim 94, wherein the method further comprises cloning of a T cell receptor (TCR) from the clonal population of peptide-specific immune effector cells.

### Claim 96 (depends on 95)

The method of claim 95, wherein cloning of the TCR is cloning of a TCR alpha and a beta chain.

### Claim 97 (depends on 95, 96)

The method of claim 95 or claim 96, wherein the TCR is cloned using a 5′-Rapid amplification of cDNA ends (RACE) method.

### Claim 98 (depends on 97)

The method of claim 97, wherein the cloned TCR is subcloned into an expression vector.

### Claim 99 (depends on 98)

The method of claim 98, wherein the expression vector is a retroviral or lentiviral vector.

### Claim 100 (depends on 98, 99)

The method of claim 98 or 99, where the method further comprises transducing a host cell with the expression vector to generate an engineered cell that expresses the TCR.

### Claim 101 (depends on 100)

The method of claim 100, wherein the host cell is an immune cell.

### Claim 102 (depends on 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101)

The method of any one of claims 73-101, wherein the immune cell is a T cell and the engineered cell is an engineered T cell.

### Claim 103 (depends on 102)

The method of claim 102, wherein the T cell is a CD8+ T cell, CD4+ T cell, or y& T cell and the engineered cell is an engineered T cell.

### Claim 104 (depends on 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103)

The method of any one of claims 73-103, wherein the starting population of immune effector cells is obtained from a subject having cancer and the host cell is allogeneic or autologous to the subject.

### Claim 105 (depends on 100, 101, 102, 103, 104)

The method of any one of claims 100-104, wherein a population of CD8 or CD4-positive and peptide MHC tetramer-positive engineered T cells are purified from the transduced host cells.

### Claim 106 (depends on 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105)

The method of any one of claims 73-105, wherein a clonal population of peptide-specific engineered T cells are generated by limiting or serial dilution followed by expansion of individual clones by a rapid expansion protocol.

### Claim 107 (depends on 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62)

A method of cloning a T cell receptor (TCR), the method comprising
(a) obtaining a starting population of immune effector cells;
(b) contacting the starting population of immune effector cells with the peptide or polypeptide of any one of claims 46-62, thereby generating peptide-specific immune effector cells;
(c) purifying immune effector cells specific to the peptide,
(d) isolating a TCR sequence from the purified immune effector cells.

### Claim 108 (depends on 107)

The method of claim 107, wherein contacting is further defined as co-culturing the starting population of immune effector cells with antigen presenting cells (APCs), wherein the APCs present the peptide on their surface.

### Claim 109 (depends on 108)

The method of claim 108, wherein the APCs are dendritic cells.

### Claim 110 (depends on 107, 108, 109)

The method of any one of claims 107-109, wherein the immune effector cells are T cells, peripheral blood lymphocytes, NK cells, invariant NK cells, NKT cells.

### Claim 111 (depends on 107, 108, 109, 110)

The method of any one of claims 107-110, wherein the immune effector cells have been differentiated from mesenchymal stem cell (MSC) or induced pluripotent stem (iPS) cells.

### Claim 112 (depends on 110, 111)

The method of claim 110 or 111, wherein the T cells are CD8+ T cells, CD4+ T cells, or γδ T cells.

### Claim 113 (depends on 110, 111, 112)

The method of any one of claims 110-112, wherein the T cells are cytotoxic T lymphocytes (CTLs).

### Claim 114 (depends on 107, 108, 109, 110, 111, 112, 113)

The method of any one of claims 107-113, wherein obtaining comprises isolating the starting population of immune effector cells from peripheral blood mononuclear cells (PBMCs).

### Claim 115 (depends on 107, 108, 109, 110, 111, 112, 113, 114)

The method of any of claims 107-114, wherein the starting population of immune effector cells is obtained from a subject.

### Claim 116 (depends on 115)

The method of claim 115, wherein the subject is a human.

### Claim 117 (depends on 115, 116)

The method of claim 115 or 116, wherein the subject has cancer.

### Claim 118 (depends on 117)

The method of claim 117, wherein the cancer comprises a VCY CT antigen positive cancer.

### Claim 119 (depends on 118)

The method of claim 118, wherein the cancer comprises cancer cells that are positive for a peptide of SEQ ID NO:15.

### Claim 120 (depends on 115, 116, 117, 118, 119)

The method of any one of claims 115-119, wherein the subject has been determined to have a VCY CT antigen positive cancer.

### Claim 121 (depends on 120)

The method of claim 120, wherein the subject has been determined to have cancer cells that are positive for a peptide of SEQ ID NO:15.

### Claim 122 (depends on 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121)

The method of any one of claims 107-121, wherein the method further comprises introducing the peptide or a nucleic acid encoding the peptide into the dendritic cells prior to the co-culturing.

### Claim 123 (depends on 122)

The method of claim 122, where the peptide or nucleic acid encoding the peptide are introduced by electroporation.

### Claim 124 (depends on 122)

The method of claim 122, wherein the peptide or nucleic acid encoding the peptide are introduced by adding the peptide or nucleic acid encoding the peptide to the media of the dendritic cells.

### Claim 125 (depends on 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124)

The method of any one of claims 109-124, wherein the immune effector cells are co-cultured with a second population of dendritic cells into which the peptide or a nucleic acid encoding the peptide has been introduced.

### Claim 126 (depends on 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125)

The method of any one of claims 107-125, wherein purifying is defined as purifying a population of CD8-positive and peptide MHC tetramer-positive T cells from the immune effector cells following the co-culturing.

### Claim 127 (depends on 126)

The method of claim 126, wherein the population of CD8-positive and peptide MHC tetramer-positive T cells are purified by fluorescence activated cell sorting (FACS).

### Claim 128 (depends on 127)

The method of claim 127, wherein purifying further comprises generation of a clonal population of peptide-specific immune effector cells by limiting or serial dilution of sorted cells followed by expansion of individual clones by a rapid expansion protocol.

### Claim 129 (depends on 128)

The method of claim 128, wherein the method further comprises cloning of a T cell receptor (TCR) from the clonal population of peptide-specific immune effector cells.

### Claim 130 (depends on 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129)

The method of any one of claims 107-129, wherein the method further comprises sequencing the TCR alpha and/or beta gene(s) and/or performing grouping of lymphocyte interactions by paratope hotspots (GLIPH) analysis.

### Claim 131 (depends on 129, 130)

The method of claim 129 or 130, wherein cloning of the TCR is cloning of a TCR alpha and a beta chain.

### Claim 132 (depends on 131)

The method of claim 131, wherein the TCR alpha and beta chains are cloned using a 5′-Rapid amplification of cDNA ends (RACE) method.

### Claim 133 (depends on 132)

The method of claim 132, wherein the cloned TCR is subcloned into an expression vector.

### Claim 134 (depends on 133)

The method of claim 133, wherein the expression vector comprises a linker domain between the TCR alpha sequence and TCR beta sequence.

### Claim 135 (depends on 134)

The method of claim 134, wherein the linker domain comprises a sequence encoding one or more peptide cleavage sites.

### Claim 136 (depends on 135)

The method of claim 135, wherein the one or more cleavage sites are a Furin cleavage site and/or a P2A cleavage site.

### Claim 137 (depends on 136)

The method of claim 136, wherein the TCR alpha sequence and TCR beta sequence are linked by an IRES sequence.

### Claim 138 (depends on 133, 134, 135, 136, 137)

The method of any of claims 133-137, wherein the expression vector is a retroviral or lentiviral vector.

### Claim 139 (depends on 138)

The method of claim 138, where a host cell is transduced with the expression vector to generate an engineered cell that expresses the TCR alpha and beta chains.

### Claim 140 (depends on 139)

The method of claim 139, wherein the host cell is an immune cell.

### Claim 141 (depends on 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140)

A peptide-specific engineered T cell produced according to any one of the methods of claims 73-140.

### Claim 142 (depends on 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138)

A TCR produced by the method of any one of claims 107-138.

### Claim 143 (depends on 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45)

A fusion protein comprising the TCR of any one of claim 28-45, or 142 and a CD3 binding region.

### Claim 144 (depends on 46)

The fusion protein of claim 46, wherein the CD3 binding region comprises a CD3-specific fragment antigen binding (Fab), single chain variable fragment (scFv), single domain antibody, or single chain antibody.

### Claim 145 (depends on 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 143, 144)

The TCR of any one of claims 28-45 or the fusion protein of claim 143 or 144, wherein the TCR or fusion protein is conjugated to a detection or therapeutic agent.

### Claim 146 (depends on 145)

The TCR or fusion protein of claim 145, wherein the agent comprises a flourescent molecule, radiative molecule, or toxin.

### Claim 147 (depends on 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 142, 143, 144, 145, 146)

A nucleic acid encoding the polypeptide of any one of claim 2-27 or 62, the TCR of any one of claim 28-45, 142, 145, or 146, the peptide of any one of claims 43-64 or the fusion protein of any one of claims 143-146.

### Claim 148 (depends on 147)

The nucleic acid of claim 147, wherein the nucleic acid is RNA.

### Claim 149 (depends on 147)

The nucleic acid of claim 147, wherein the nucleic acid is DNA or a cDNA encoding the peptide or polypeptide or a complement of the peptide or polypeptide.

### Claim 150 (depends on 147)

The nucleic acid of claim 147, wherein the nucleic acid has at least 70% sequence identity to one of SEQ ID NOS: 1, 2, or a fragment thereof.

### Claim 151 (depends on 147, 148, 149, 150)

A nucleic acid expression vector comprising the nucleic acid(s) of any one of claims 147-150.

### Claim 152 (depends on 151)

The vector of claim 151, wherein the vector comprises a promoter that directs the expression of the nucleic acid.

### Claim 153 (depends on 152)

The vector of claim 152, wherein the promoter comprises a murine stem cell virus (MSCV) promoter.

### Claim 154 (depends on 151, 152, 153)

The vector of any one of claims 151-153, wherein the vector comprises the TCR-a and TCR-b genes.

### Claim 155 (depends on 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 62, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154)

A cell comprising the polypeptide of any one of claim 2-27 or 62, TCR of any one of claim 28-45, 142, 145, or 146, the fusion protein of any one of claims 143-146, the nucleic acid(s) of any one of claims 147-150, or the vector of any one of claims 151-154.

### Claim 156 (depends on 155)

The cell of claim 155, wherein the cell comprises a stem cell, a progenitor cell, an immune cell, or a natural killer (NK) cell.

### Claim 157 (depends on 156)

The cell of claim 156, wherein the cell comprises a hematopoietic stem or progenitor cell, a T cell, a cell differentiated from mesenchymal stem cells (MSCs) or an induced pluripotent stem cell (iPSC).

### Claim 158 (depends on 156, 157)

The cell of claim 156 or 157, wherein the cell is isolated or derived from peripheral blood mononuclear cell (PBMCs).

### Claim 159 (depends on 157, 158)

The cell of claim 157 or 158, wherein the T cell comprises a cytotoxic T lymphocyte (CTL), a CD8+ T cell, a CD4+ T cell, an invariant NK T (INKT) cell, a gamma-delta T cell, a NKT cell, or a regulatory T cell.

### Claim 160 (depends on 155, 156, 157, 158, 159)

The cell of any one of claims 155-159, wherein the cell is isolated from a cancer patient.

### Claim 161 (depends on 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 147, 148, 149, 150, 151, 152, 153, 154)

An in vitro isolated dendritic cell comprising the peptide or polypeptide of any one of claim 46-61 or 62, the nucleic acid of any one of claims 147-150, or the vector of any one of claims 151-154.

### Claim 162 (depends on 161)

The dendritic cell of claim 161, wherein the dendritic cell is a mature dendritic cell.

### Claim 163 (depends on 161, 162)

The dendritic cell of claim 161 or 162, wherein the cell is a cell with an HLA-A, HLA-B, or HLA-C type.

### Claim 164 (depends on 163)

The dendritic cell of claim 163, wherein the cell is a HLA-A or a HLA-A*1101 type.

### Claim 165 (depends on 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 62, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164)

A composition comprising the polypeptide of any one of claim 2-27 or 62, TCR of any one of claim 28-45, 142, 145, or 146, the fusion protein of any one of claims 143-146, the nucleic acid(s) of any one of claims 147-150, the vector of any one of claims 151-154, or the cell of any one of claims 155-164.

### Claim 166 (depends on 165)

The composition of claim 165, wherein the composition is formulated for parenteral administration, intravenous injection, intramuscular injection, inhalation, or subcutaneous injection.

### Claim 167 (depends on 165, 166)

The composition of claim 165 or 166, wherein the peptide is comprised in a liposome, lipid-containing nanoparticle, or in a lipid-based carrier.

### Claim 168 (depends on 165, 166, 167)

The composition of any one of claims 165-167, wherein the composition is formulated as a vaccine.

### Claim 169 (depends on 165, 166, 167, 168)

The composition of any one of claims 165-168, wherein the composition further comprises an adjuvant.

### Claim 170 (depends on 165, 166, 167, 168, 169)

The composition of any one of claims 165-169, wherein the composition has been determined to be serum-free, mycoplasma-free, endotoxin-free, and/or sterile.

### Claim 171 (depends on 147, 148, 149, 150, 151, 152, 153, 154)

A method of making an engineered cell comprising the nucleic acid(s) of any one of claims 147-150 or the vector of any one of claims 151-154 into a cell.

### Claim 172 (depends on 171)

The method of claim 171, wherein the method further comprises culturing the cell in media, incubating the cell at conditions that allow for the division of the cell, screening the cell, and/or freezing the cell.

### Claim 173 (depends on 141, 155, 156, 157, 158, 159, 160, 165, 166, 167, 168, 169, 170)

A method for treating cancer in a subject comprising administering the composition of any one of claims 165-170 or the cells of any one of claim 141 or 155-160 to a subject in need thereof.

### Claim 174 (depends on 141, 155, 156, 157, 158, 159, 160, 165, 166, 167, 168, 169, 170)

A method for treating or preventing cancer in a subject comprising administering the composition of any one of claims 165-170 or the cells of any one of claim 141 or 155-160 to a subject in need thereof.

### Claim 175 (depends on 173, 174)

The method of claim 173 or 174, wherein the cancer is selected from non-small cell lung cancer and melanoma.

### Claim 176 (depends on 141, 155, 156, 157, 158, 159, 160, 165, 166, 167, 168, 169, 170)

A method of stimulating an immune response in a subject, the method comprising administering the composition of any one of claims 165-170 or the cells of any one of claim 141 or 155-160 to a subject in need thereof.

### Claim 177 (depends on 173, 174, 175, 176)

The method of any one of claims 173-176, wherein the subject is a human subject.

### Claim 178 (depends on 173, 174, 175, 176, 177)

The method of any one of claims 173-177, wherein the cells are autologous.

### Claim 179 (depends on 173, 174, 175, 176, 177)

The method of any one of claims 173-177, wherein the cells are allogenic.

### Claim 180 (depends on 173, 174, 175, 176, 177, 178, 179)

The method of any one of claims 173-179, wherein the subject has previously been treated for the cancer.

### Claim 181 (depends on 180)

The method of claim 180, wherein the subject has been determined to be resistant to the previous treatment.

### Claim 182 (depends on 173, 174, 175, 176, 177, 178, 179, 180, 181)

The method of any one of claims 173-181, wherein the method further comprises the administration of an additional therapy.

### Claim 183 (depends on 173, 174, 175, 176, 177, 178, 179, 180, 181, 182)

The method of any one of claims 173-182, wherein the cancer comprises stage I, II, III, or IV cancer.

### Claim 184 (depends on 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183)

The method of any one of claims 173-183, wherein the cancer comprises metastatic and/or recurrent cancer.

### Claim 185 (depends on 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184)

The method of any one of claims 173-184, wherein the cancer is a VCY CT antigen positive cancer.

### Claim 186 (depends on 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185)

The method of any one of claims 173-185, wherein the subject has been determined to have VCY CT antigen positive cancer cells.

### Claim 187 (depends on 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185)

The method of any one of claims 173-185, wherein the subject has been determined to have cancer cells that express a peptide of SEQ ID NO:15.

### Claim 188 (depends on 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187)

The method of any one of claims 173-187, wherein the subject is and/or has been determined to be HLA-A positive.

### Claim 189 (depends on 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185)

The method of claim 173-185, wherein the subject is and/or has been determined to be HLA-A1101 positive.

### Claim 190 (depends on 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 70)

A method for prognosing a patient or for detecting T cell responses in a patient, the method comprising: contacting a biological sample from the patient with the peptide or polypeptide of any one of claims 46-61 or the molecular complex of claim 70.

### Claim 191 (depends on 190)

The method of claim 190, wherein the biological sample comprises a blood sample or a fraction thereof.

### Claim 192 (depends on 191)

The method of claim 191, wherein the biological sample comprises lymphocytes.

### Claim 193 (depends on 192)

The method of claim 192, wherein the biological sample comprises a fractionated sample comprising lymphocytes.

### Claim 194 (depends on 190, 191, 192, 193)

The method of any one of claims 190-193, wherein the peptide is linked to a solid support.

### Claim 195 (depends on 194)

The method of claim 194, wherein the peptide is conjugated to the solid support or is bound to an antibody that is conjugated to the solid support.

### Claim 196 (depends on 194)

The method of claim 194, wherein the solid support comprises a microplate, a bead, a glass surface, a slide, or a cell culture dish.

### Claim 197 (depends on 190, 191, 192, 193, 194, 195, 196)

The method of any one of claims 190-196, wherein detecting T cell responses comprises detecting the binding of the peptide to the T cell or TCR.

### Claim 198 (depends on 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62)

A kit comprising the peptide or polypeptide of any one of claims 46-62 in a container.

### Claim 199 (depends on 198)

The kit of claim 198, wherein the peptide is comprised in a pharmaceutical preparation.

### Claim 200 (depends on 199)

The kit of claim 199, wherein the pharmaceutical preparation is formulated for parenteral administration or inhalation.

### Claim 201 (depends on 198)

The kit of claim 198, wherein the peptide is comprised in a cell culture media.
